

# Human SETD7 Protein

Cat. No. SED-HM107



## Description

<b>Source</b>	Recombinant Human SETD7 Protein is expressed from E.coli with His tag at the N-Terminus. It contains Met1-Lys366.
<b>Accession</b>	NP_085151.1
<b>Molecular Weight</b>	The protein has a predicted MW of 41.68 kDa. The protein migrates to 47-50 kDa based on Bis-Tris PAGE result.
<b>Endotoxin</b>	Less than 1EU per µg by the LAL method.
<b>Purity</b>	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC

## Formulation and Storage


<b>Formulation</b>	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
<b>Reconstitution</b>	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
<b>Storage</b>	-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

## Background

SETD7 is a methyltransferase that specifically catalyzes the monomethylation of lysine 4 on histone H3. A variety of studies has revealed the role of SETD7 in posttranslational modifications of non-histone proteins. Aberrant expression of SETD7 has been associated with various diseases, including cancer. As a prognostic marker of breast cancer and a novel antioxidant promoter under oxidative stress in breast cancer, SETD7 is considered a good target for the development of new epigenetic drugs.


## Assay Data

### Bis-Tris PAGE



Human SETD7 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

### SEC-HPLC



The purity of Human SETD7 is greater than 95% as determined by SEC-HPLC.